A drug candidate developed by Sanofi and the Drugs for Neglected Diseases initiative (DNDi) has shown very high efficacy in treating sleeping sickness, a sometimes lethal condition that is endemic across Sub-Saharan Africa. Read More

In the wake of twin phase 3 failures, Roche will discontinue all active trials of the antiamyloid antibody gantenerumab, the company confirmed at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco. Read More

TauRx went big at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in San Francisco, insisting that its investigational anti-tau agent, hydromethylthionine mesylate (HMTM), exerted cognitive benefit and slowed brain atrophy in an ongoing phase 3 trial — despite a prior admission that a blinded study of the drug is virtually impossible. Read More

Eisai’s antiamyloid antibody lecanemab nearly eliminated amyloid brain plaques in 68 percent of Alzheimer’s (AD) patients, while modestly slowing decline on all four cognitive and functional measures in the CLARITY AD study, company executives and clinicians involved in the study said at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco. Read More

Axsome Therapeutics’ proprietary combination of dextromethorphan and bupropion — already approved for major depressive disorder as AXS-05 — also reduced the risk of agitation related to Alzheimer’s disease (AD), the company reported. Read More

Lysogene’s investigational gene therapy LYS-SAF302 preserved cognitive function and brain volume in a small set of infants with a devastating type of childhood dementia, mucopolysaccharidosis Type IIIA (MPS IIIA). Read More

Sellas Life Sciences is amending the statistical analysis in an ongoing phase 3 trial for acute myeloid leukemia after a preliminary data review found that patients enrolled were living twice as long as originally projected. Read More

Addressing sponsors’ desires to evaluate multiple versions of cell and gene therapy candidates in a single early phase trial, the FDA has issued guidance that encourages separate Investigational Drug Applications (INDs) but under an umbrella trial design. Read More

Neurotech Pharmaceuticals has announced positive phase 3 topline results from two trials evaluating its NT-501 eye treatment for patients with macular telangiectasia type 2 (MacTel). Read More